$NNOX

Nano-X Imaging Ltd.

Insider trades

No enriched coverage for $NNOX in the last 7 days.

$110K
$890
Suesskind Dan S
0%
See all $NNOX insider activity →
Low

Suesskind Dan S purchased $46K of NNOX

Suesskind Dan S purchased 50,000 shares of Nano-X Imaging Ltd. (NNOX) at an average of $0.93 ($0.92–$0.94) across 2 trades on 2026-07-27.

NNOX sentiment & insider activity

Recent NNOX coverage spans financial news, insider activity and technology.

In the last 30 days, NNOX insiders filed 5 SEC Form 4 transactions — 4 purchases ($110K) and 1 sale ($890). The most active reporter was Suesskind Dan S with 2 filings.

What's driving NNOX

  • This is an insider buy, but the filing does not disclose new company fundamentals beyond the transaction itself.

    SEC EDGAR · Jul 29, 2026

  • A director open-market buy is a modest, sentiment-supportive signal, but it is not a fundamental catalyst by itself.

    SEC EDGAR · Jul 29, 2026

  • The filing is a small insider buy that may modestly support sentiment, but it is not a fundamental catalyst by itself.

    SEC EDGAR · Jul 28, 2026

  • Conference-bound clinical-trial/validation updates for HealthCCSng could modestly improve investor confidence in Nanox.AI’s clinical evidence pipeline, but it’s not a regulatory or commercialization milestone.

    finanznachrichten.de · Jul 7, 2026

  • Completion of a commercial-ready One-Pot LFP CAM package and bundling of license/process/equipment is a tangible commercialization milestone that can improve near-term licensing pipeline expectations.

    finanznachrichten.de · Jun 25, 2026

alphai scores every news story that mentions NNOX with an AI model for sentiment and relevance, and aggregates insider trades from Nano-X Imaging Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NNOX

Score

NANO-X IMAGING LTD: New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026

Nanox Imaging Ltd. (NASDAQ: NNOX) said clinical study data on its Nanox.AI FDA-cleared cardiac AI solution (HealthCCSng) will be presented at SCCT 2026. The AI INFORM trial and a multi-site analysis will report agreement between AI-detected coronary artery calcium and expert assessment, according to abstracts from Brigham and Women’s Hospital and others.

Nano One Materials Corp.: Nano One and Worley Chemetics Complete One-Pot LFP Cathode Package and Advance to Market

Nano One Materials Corp. said it and alliance partner Worley Chemetics have completed a “One-Pot” lithium iron phosphate (LFP) cathode active material package, using qualified equipment vendors in North America, Europe and South Africa, meeting a Class 3 cost estimate and targeting first-half 2026 marketing. The package bundles a technology license, process design and qualified equipment; a hybrid configuration for H2 2026 adds optional Chinese sourcing for non-IP-sensitive equipment.

Related tickers